ClinicalTrials.gg

Program

anlotinib

Also written as “Anlotinib”, “AL3818” and “AK104+anlotinib”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Endometrial Neoplasms · Small Cell Lung Carcinoma · Neoplasms · Sarcoma, led by 8 companies.

Furthest: phase 3, since Dec 30, 201340 company-led studies, 7 open or runningNext primary completion: Mar 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical311 open or runningphase 3since Dec 30, 2013Mar 29, 2013none ahead
Advenchen Laboratories32 open or runningphase 3since Aug 28, 2015Sep 26, 2014Dec 2027phase 3 · NCT03016819
Advenchen Laboratories Nanjing11 open or runningphase 1since Feb 11, 2026Feb 11, 2026Mar 31, 2027phase 1 · NCT07438886
Advenchen Pharmaceuticals, LLC.11 open or runningphase 2since Aug 12, 2026Aug 12, 2026Sep 1, 2030phase 2 · NCT07811297
Akeso10 open or runningphase 2since Nov 23, 2020Nov 23, 2020none ahead
Fosun Pharma11 open or runningphase 2since Apr 25, 2026Apr 25, 2026Jun 2029phase 2 · NCT07562581
Lyvgen Biopharma10 open or runningphase 2since Mar 2, 2022Mar 2, 2022none ahead
Shanghai Gopherwood Biotech11 open or runningphase 2since Jan 12, 2023Jan 12, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 27 studies since Mar 29, 2013.

  1. Sep 25, 2019Phase 2 study in Gastrointestinal Stromal TumorsSino Biopharmaceutical · NCT04106024 · 60 enrolled · China
  2. Dec 30, 2019Phase 2 study in Advanced MalignancySino Biopharmaceutical · NCT04216082 · 93 enrolled · China
  3. Jan 16, 2020Phase 3 study in Extensive Small Cell Lung CancerSino Biopharmaceutical · NCT04234607 · 738 enrolled · China
  4. Mar 25, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungSino Biopharmaceutical · NCT04325763 · 315 enrolled · China
  5. Sep 30, 2020Phase 2 study in Advanced Endometrial CancerSino Biopharmaceutical · NCT04574284 · 170 enrolled · China
  6. Nov 23, 2020Akeso's first study: phase 2 study in NSCLCNew to AkesoAkeso · NCT04646330 · 114 enrolled · China
  7. Mar 2, 2022Lyvgen Biopharma's first study: phase 2 study in SarcomaNew to Lyvgen BiopharmaLyvgen Biopharma · NCT05301764 · 39 enrolled · China
  8. Jan 12, 2023Shanghai Gopherwood Biotech's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Shanghai Gopherwood BiotechShanghai Gopherwood Biotech · NCT05715398 · 90 planned
  9. Jun 17, 2024Phase 3 study in Small Cell Lung Cancer Limited StageSino Biopharmaceutical · NCT06469879 · 358 planned · China
  10. Jul 11, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungSino Biopharmaceutical · NCT06507891 · 30 enrolled · China
  11. Feb 11, 2026Advenchen Laboratories Nanjing's first study: phase 1 study in Healthy VolunteerNew to Advenchen Laboratories NanjingAdvenchen Laboratories Nanjing · NCT07438886 · 16 planned · China
  12. Apr 25, 2026Fosun Pharma's first study: phase 2 study in Neoplasm MetastasisNew to Fosun PharmaFosun Pharma · NCT07562581 · 48 planned · China
  13. Aug 12, 2026Advenchen Pharmaceuticals, LLC.'s first study: phase 2 study in Endometrial NeoplasmsNew to Advenchen Pharmaceuticals, LLC.Advenchen Pharmaceuticals, LLC. · NCT07811297 · 138 planned · United States
  14. Nov 16, 2026Primary completion moved from 2027-11 to 2028-12Date moved laterphase 2 · +13 months · NCT07548177

Ahead

  1. Mar 31, 2027Primary completion: phase 1 study in Healthy VolunteerAdvenchen Laboratories Nanjing · NCT07438886
  2. Dec 2027Primary completion: phase 3 study in Sarcoma, Alveolar Soft PartAdvenchen Laboratories · NCT03016819
  3. Jun 2029Primary completion: phase 2 study in Neoplasm MetastasisFosun Pharma · NCT07562581
  4. Sep 1, 2030Primary completion: phase 2 study in Endometrial NeoplasmsAdvenchen Pharmaceuticals, LLC. · NCT07811297

TargetBeta

“Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
regorafenibruleBayerphase 440

Studies

All 40 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07811297Endometrial Neoplasms · United States2Not yet recruitingAdvenchen Pharmaceuticals, LLC.Sep 1, 2030138
NCT07562581Neoplasm Metastasis · China2RecruitingFosun PharmaJun 202948
NCT07438886Healthy Volunteer · China1Not yet recruitingAdvenchen Laboratories NanjingMar 31, 202716
NCT06507891Carcinoma, Non-Small-Cell Lung · China2TerminatedSino BiopharmaceuticalAug 25, 202330
NCT06469879Small Cell Lung Cancer Limited Stage · China3Not yet recruitingSino BiopharmaceuticalSep 2026358
NCT05715398Carcinoma, Non-Small-Cell Lung2Not yet recruitingShanghai Gopherwood BiotechDec 202490
NCT05301764Sarcoma · China2CompletedLyvgen BiopharmaDec 19, 202539
NCT04646330NSCLC · China2CompletedAkesoOct 26, 2023114
NCT04574284Advanced Endometrial Cancer · China2CompletedSino BiopharmaceuticalNov 9, 2023170
NCT04325763Carcinoma, Non-Small-Cell Lung · China3UNKNOWNSino BiopharmaceuticalDec 2022315
NCT04234607Extensive Small Cell Lung Cancer · China3UNKNOWNSino BiopharmaceuticalDec 2022738
NCT04216082Advanced Malignancy · China2CompletedSino BiopharmaceuticalAug 31, 201493
NCT04106024Gastrointestinal Stromal Tumors · China2UNKNOWNSino BiopharmaceuticalOct 30, 201960
NCT04073550Small Cell Lung Carcinoma · China3UNKNOWNSino BiopharmaceuticalJul 31, 2021184
NCT04073537Squamous Non-small Cell Lung Cancer · China3UNKNOWNSino BiopharmaceuticalJul 31, 2021386
NCT03825705Carcinoma, Hepatocellular · China2UNKNOWNSino BiopharmaceuticalJan 1, 202160
NCT03527888Bone Neoplasms · China2UNKNOWNSino BiopharmaceuticalDec 31, 201940
NCT03457844Gastroenteropancreatic Neuroendocrine Tumor G3 · China2UNKNOWNSino BiopharmaceuticalAug 30, 201960
NCT03059797Small Cell Lung Carcinoma · China2CompletedSino BiopharmaceuticalJun 30, 2018120
NCT03016819Sarcoma, Alveolar Soft Part · United States, China, Italy and more3RecruitingAdvenchen LaboratoriesDec 2027325
NCT02825563Advanced Cancer · China1CompletedSino BiopharmaceuticalAug 15, 201822
NCT02809534Carcinoma, Hepatocellular · China2UNKNOWNSino BiopharmaceuticalDec 201760
NCT02752516Neoplasms · China1UNKNOWNSino BiopharmaceuticalDec 201716
NCT02649361Esophageal Squamous Cell Carcinoma · China2CompletedSino BiopharmaceuticalJul 23, 2018164
NCT02622932Advanced Solid Tumors · China1CompletedSino BiopharmaceuticalDec 30, 20166
NCT02586350Carcinoma, Medullary · China3CompletedSino BiopharmaceuticalSep 30, 201891
NCT02586337Differentiated Thyroid Cancer · China3UNKNOWNSino BiopharmaceuticalDec 2019113
NCT02584478Endometrial Neoplasms · United States, China, Italy and more3Active, not recruitingAdvenchen LaboratoriesOct 2024294
NCT02461407Stomach Neoplasms · China3UNKNOWNSino BiopharmaceuticalDec 2017378
NCT02449343Sarcoma · China3UNKNOWNSino BiopharmaceuticalApr 2017233
NCT02388919Carcinoma, Non-Small-Cell Lung · China3CompletedSino BiopharmaceuticalJan 5, 2017439
NCT02332499Colorectal Neoplasms · China3CompletedSino BiopharmaceuticalAug 18, 2016419
NCT02558348Endometrial Neoplasms · United States2TerminatedAdvenchen LaboratoriesFeb 14, 201712
NCT02072044Carcinoma, Renal Cell · China2UNKNOWNSino BiopharmaceuticalDec 201760
NCT02072031Anlotinib · China2UNKNOWNSino BiopharmaceuticalDec 2016133
NCT02029209Carcinoma, Non-Small-Cell Lung · China3UNKNOWNSino BiopharmaceuticalMar 2017110
NCT01924195Carcinoma, Non-Small-Cell Lung · China2CompletedSino BiopharmaceuticalMar 2015117
NCT01878448Neoplasms · China2CompletedSino BiopharmaceuticalOct 2015166
NCT01874873Neoplasms · China2CompletedSino BiopharmaceuticalDec 201658
NCT01833923Advanced Cancer · China1CompletedSino BiopharmaceuticalOct 201535

How it is read

Names in the registry

  • “Anlotinib”, 27 entries
  • “AL3818”, 5 entries
  • “AK104+anlotinib”, 3 entries
  • “luvometinib + anlotinib”, 2 entries
  • “Anlotinib and 14C-labeled Anlotinib”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.